China-based Innovent Biologics has entered USD 11.4 billion strategic partnership with Japan's Takeda, including a USD 1.2 billion upfront payment with USD 100 million equity investment for the global co-development and commercialisation of PD-1/IL-2α bispecific antibody (BsAb) IBI363 and CLDN18.2 antibody-drug conjugate (ADC) IBI343. The agreement represents the largest out-licensing deal in Chinese biopharmaceutical history, featuring a profit-sharing arrangement in the US market and a collaborative development model for next-generation oncology candidates.

IBI363 addresses limitations in cold tumours including pancreatic and liver cancers, with potential expansion beyond PD-1-responsive populations. Meanwhile, IBI343 demonstrates 58% objective response rate (ORR) in CLDN18.2-positive gastric and pancreatic cancers. Takeda's global commercial infrastructure covering 86 countries will accelerate market penetration following regulatory approvals, with Innovent retaining co-promotion rights and substantial profit participation.

According to PharmCube's NextBiopharm® database, the deal overshadows the total value of Innovent's past licensing transactions. Click here to request a free trial for NextBiopharm®.